What 4 Analyst Ratings Have To Say About Emergent BioSolutions
Portfolio Pulse from Benzinga Insights
In the last 3 months, 4 analysts have offered 12-month price targets for Emergent BioSolutions (NYSE:EBS), with an average price target of $18.75, representing an 18.48% decrease from the previous average of $23.00. The company has received 3 bullish ratings and 1 somewhat bearish rating.
May 31, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Emergent BioSolutions (NYSE:EBS) has an average 12-month price target of $18.75, down 18.48% from the previous average, with 3 bullish and 1 somewhat bearish ratings.
The average 12-month price target for EBS has decreased by 18.48% from the previous average, indicating a potential negative sentiment among analysts. However, the majority of ratings are still bullish, which suggests a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100